SCHEMBL3567994

SCHEMBL3567994

CN1CCN(c2ccc(NC=C3C(=O)NC(=O)c4ccc(I)cc43)cc2F)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 2/20 0.38
APP P05067 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CRBN Q96SW2 1/20 0.35
CCNT1 O60563 2/20 0.35
CDK4 P11802 2/20 0.35
CCND1 P24385 2/20 0.35
CCND3 P30281 2/20 0.35
CDK9 P50750 2/20 0.35
CDK6 Q00534 2/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567990 1.00 KDM4E (0.45) KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL3565294 0.89 KDM4E (0.43) KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL3565291 0.89 KDM4E (0.43) KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL3567885 0.87 AXL (0.43) KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL3567888 0.87 AXL (0.43) KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL3565957 0.85 KDM4E (0.40) KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL3565953 0.85 KDM4E (0.40) KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL3570748 0.85 CSF1R (0.42) NPC1RAB9AMAPTAPPMEN1
SCHEMBL3570751 0.85 CSF1R (0.42) NPC1RAB9AMAPTAPPMEN1
SCHEMBL3568339 0.85 APP (0.35) MAPTAPPCDK4CCND1TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US claimed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US claimed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
EP-1963273-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2008-09-03 EP disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed
WO-2007075783-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR WYETH (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof SULT1E1, RECQL, HAX1 KDM4E 2158/4885L3MBTL1 838/4885NPC1 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.